D-VRd Boosts MRD-Negativity Rates in Newly Diagnosed, Transplant-Eligible Multiple Myeloma
Avelumab Plus Cisplatin-Based Chemotherapy Yields High EFS and OS Rates in MIUC
Isa-VRd Prolongs PFS in Newly Diagnosed, Transplant-Ineligible Multiple Myeloma
Dostarlimab 2 for 2: Snagging 100% Clinical CR in dMMR Locally Advanced Rectal Cancer